# Cleaning the sleeping brain: Can drugs restore the glymphatic system?
A new review in Current Neuropharmacology maps out what goes wrong when the brain’s waste clearance system breaks down — and surveys the drugs that might fix it. The authors, led by Souvik Banerjee and colleagues from Chitkara University, India, argue that aquaporin-4 (AQP4) water channels on astrocytic endfeet are the most direct therapeutic target, but also the hardest to hit safely.
## How the cleanup crew works
The glymphatic system flushes waste out of the brain. Cerebrospinal fluid enters along periarterial spaces, mixes with interstitial fluid, and drains along perivenous routes. The key players are AQP4 water channels anchored at astrocytic endfeet — the interface between brain cells and blood vessels. When these channels are properly polarized at the blood-brain barrier, the convective flow works. When they’re not, the system stalls.
Glymphatic activity isn’t constant. It peaks during sleep, when the brain’s extracellular space expands and fluid resistance drops. Animal studies and human work have both confirmed this sleep-dependence. Recent research in Nature Communications showed that sleep enhances overnight clearance of amyloid-beta and tau into the bloodstream, linking sleep quality directly to how efficiently the brain clears neurotoxic proteins.
## What goes wrong
Glymphatic efficiency declines with age, vascular stiffening, and neuroinflammation. Several interconnected pathways contribute. Dysregulated NF-kB signaling promotes inflammation and disrupts AQP4 localization. Impaired Nrf2/Keap1 antioxidant defenses leave the system vulnerable to oxidative stress. NLRP3 inflammasome activation amplifies neuroinflammatory cascades that further disrupt fluid dynamics.
The result is a self-reinforcing loop: impaired clearance lets neurotoxic proteins accumulate, which triggers glial activation and more inflammation, which worsens AQP4 mislocalization and cuts clearance further. This cycle is increasingly tied to Alzheimer’s, Parkinson’s, and other neurodegenerative conditions. A 2025 review in Acta Neuropathologica Communications similarly identified glymphatic dysfunction as a critical mechanism connecting sleep disruption to neurodegeneration.
## The drug pipeline
The review identifies several intervention strategies. Fixing AQP4 polarization is the most direct approach, but achieving isoform-selective modulation without disrupting water homeostasis in the rest of the body remains a major pharmacological hurdle. Compounds targeting upstream regulators — anti-inflammatories that dampen NF-kB signaling, antioxidants that activate the Nrf2 pathway — have shown preclinical promise.
Getting drugs to the right place is half the problem. The blood-brain barrier has traditionally blocked candidate therapeutics. Newer delivery technologies, including nanocarriers and nose-to-brain routes, offer ways to direct AQP4 modulators and anti-inflammatory agents to the perivascular space where glymphatic exchange happens.
## What’s holding the field back
Translating this work from rodents to humans is hard. The human brain is larger, has different CSF dynamics, and relies on different pressure gradients. Non-invasive imaging of glymphatic function in humans is still in early development. Long-term safety data for AQP4-targeting compounds doesn’t exist, and disrupting water homeostasis in the brain — even temporarily — carries unknown risks.
## Bottom line
The glymphatic system is one of the clearest physiological links between sleep and brain health. Restoring AQP4 function and the clearance pathways it supports could slow neurodegenerative disease progression. But the gap between an attractive target and a safe drug remains wide.
**Source:** Banerjee S, Singh S, Singh TG. “Reviving Brain Waste Clearance: A Pharmacological Perspective on Glymphatic Dysfunction and AQP4 Modulation.” *Current Neuropharmacology*, 2026. DOI: 10.2174/011570159X433721260101212425.